The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Tumor necrosis factor α blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue
Abstract
Objective: To determine whether treatment with the chimeric anti–tumor necrosis factor α antibody infliximab could reduce cellularity by the induction of apoptosis in synovial tissue. Methods: Twenty‐four rheumatoid arthritis patients with active disease were randomized to receive either infliximab (3 mg/kg) (n = 12) or placebo (n = 12) intravenously. All patients were subjected to arthroscopic synovial biopsy directly before initiation of treatment. A second arthroscopic synovial biopsy of the same index joint was performed 48 hours after the first arthroscopy. After the second arthroscopy, the patients who had initially received placebo were also treated with infliximab in an extension study. A third arthroscopy was performed in all patients on day 28. Immunohistologic analysis was performed to characterize the cell infiltrate. In situ detection of apoptotic cells was performed by TUNEL assay and electron microscopy. Results: At 48 hours after initiation of infliximab treatment, there was a significant reduction in the number of intimal macrophages; this was not observed in the placebo group. The number of sublining macrophages, T cells, and plasma cells also tended to be decreased in infliximab‐treated patients, but not in the placebo group. Of interest, we did not detect any increase in the number of apoptotic cells after infliximab treatment. Conclusion: Infliximab therapy may reduce the number of inflammatory cells in rheumatoid synovial tissue as soon as 48 hours after initiation of treatment, but apparently not by induction of apoptosis. Conceivably, decreased cell infiltration primarily results from early inhibition of cell migration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Elliott, M. J., Maini, R. N., Feldmann, M., Kalden, J. R., Antoni, C., Smolen, J. S., Leeb, B., Breedveld, F. C., Macfarlane, J. D., Bijl, J. A., et al. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90628-9 · Cited by 1,682
Warrington (2001) · Pure Amsterdam UMC · doi:10.1002/1529-0131(200101)44:1 · Cited by 2
Cited by
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
Tracey, D., Klareskog, L., Sasso, E. H., Salfeld, J. G., & Tak, P. P. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.10.001 · Cited by 1,628
Self-citationPathirana, D., Ormerod, A., Saiag, P., Smith, C., Spuls, P., Nast, A., Barker, J., Bos, J., Burmester, G., Chimenti, S., et al. (2009) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2009.03389.x · Cited by 703
Haringman, J. J., Gerlag, D. M., Zwinderman, A. H., Smeets, T. J. M., Kraan, M. C., Baeten, D., McInnes, I. B., Bresnihan, B., & Tak, P. P. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.029751 · Cited by 457
Self-citationChen, Y.-F., Jobanputra, P., Barton, P., Jowett, S., Bryan, S., Clark, W., Fry-Smith, A., & Burls, A. (2006) · Health Technology Assessment · doi:10.3310/hta10420 · Cited by 406
Mor, A., Abramson, S. B., & Pillinger, M. H. (2005) · Clinical Immunology · doi:10.1016/j.clim.2004.12.009 · Cited by 399
Metadata
- Authors
- Smeets, T. J. M., Kraan, M. C., van Loon, M. E., & Tak, P.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2003-08
- Volume
- 48
- Issue
- 8
- Pages
- 2155-2162
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2039671281
- Cited by
- 224
- References
- 2
- FWCI
- 13.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tumor necrosis factor α blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. https://app.cochat.ai/papers/10.1002/art.11098
- The paper
- Smeets, T. J. M., Kraan, M. C., van Loon, M. E., & Tak, P. (2003). Tumor necrosis factor α blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis & Rheumatism. https://doi.org/10.1002/art.11098
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.